


Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)



Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/996,484
		Filing Date	November 28, 2001
		First Named Inventor	CHOO
		Group Art Unit	1645/636
		Examiner Name	Unassigned
Sheet 1 of 2	Attorney Docket Number	8325-2008 (G8-US1)	

RECEIVED

NOV 06 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
DS	B1	WO	92/00388	A1	The Regents of the University of California	01-09-1992	
	B2	WO	93/23431	A1	Baylor College of Medicine	11-25-1993	
	B3	WO	94/29442	A2	BASF Aktiengesellschaft	12-22-1994	
	B4	WO	95/20652	A1	Altmann, Herbert	08-03-1995	
	B5	WO	96/01313	A1	Bujard, Hermann	01-18-1996	
	B6	WO	96/06166	A1	Medical Research Council	02-29-1996	
	B7	WO	96/20951	A1	Massachusetts Institute of Technology	07-11-1996	
	B8	WO	96/40892	A1	BASF AG	12-19-1996	
	B9	WO	96/41865	A1	Ariad Gene Therapeutics, Inc.	12-27-1996	
	B10	WO	97/10337	A1	Baylor College of Medicine	03-20-1997	
	B11	WO	97/31113	A1	Ariad Pharmaceuticals, Inc.	08-28-1997	
	B12	WO	98/25947	A1	Bristol-Myers Squibb Company	06-18-1998	
	B13	WO	98/53057	A1	Medical Research Council	11-26-1998	
	B14	WO	99/01549	A1	BASF Aktiengesellschaft	01-14-1999	
DS	B15	WO	99/10510	A2	Ariad Gene Therapeutics, Inc.	03-04-1999	
	B16	WO	00/73434	A1	Gendaq Limited	12-07-2000	

Examiner Signature	<i>DS</i>	Date Considered	5/13/04
--------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/996,484
		Filing Date	November 28, 2001
		First Named Inventor	CHOO
		Group Art Unit	1645 / 636
Examiner Name	Unassigned	NOV 03 2003	
Sheet	2	of	2
Attorney Docket Number		8325-2008 (G8-US1)	

RECEIVED

TECH CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DS	C1	Dickinson et al., "Inhibition of RNA Polymerase II Transcription in Human Cells by Synthetic DNA-Binding Ligands," <i>PNAS</i> 95(22):12890-12895 (1998)	
	C2	Dickinson et al., "Inhibition of Ets-1 DNA Binding and Ternary complex Formation Between Ets-1, NF-KappaB, and DNA by a Designed DNA-Binding Ligand," <i>Journal of Biological Chemistry</i> 274(18):12765-12773 (1999)	
	C3	Gatz et al., "Stringent Repression and Homogenous De-Repression by Tetracycline of a Modified CaMV 35S Promoter in Intact Transgenic Tobacco Plants," <i>Plant Journal</i> 2(3):397-404 (1992)	
	C4	Gottesfeld et al., "Regulation of Gene Expression by Small Molecules," <i>Nature</i> 387(6629):202-205 (1997)	
DS	C5	Weinmann et al., "Chimeric Transactivator Allows Tetracycline-Responsive Gene Expression in Whole Plants," <i>Plant Journal</i> 5(4):559-569 (1994)	

Examiner Signature		Date Considered	5/13/04
---------------------------	---	------------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.

DIPE JC150
APR 16 2004
PATENT & TRADEMARK

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
Sheet	1	of	2
		Application Number	09/996,484
		Filing Date	November 28, 2001
		First Named Inventor	CHOO
		Group Art Unit	1645 / 636
		Examiner Name	Unassigned D. Sullivan
		Attorney Docket Number	8325-2008 (G8-US1)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
S S S S S S S S S S S S S S S S	B1	WO	92/00388	A1	The Regents of the University of California	01-09-1992	
	B2	WO	93/23431	A1	Baylor College of Medicine	11-25-1993	
	B3	WO	94/29442	A2	BASF Aktiengesellschaft	12-22-1994	
	B4	WO	95/20652	A1	Altmann, Herbert	08-03-1995	
	B5	WO	96/01813	A1	Bujard, Hermann	01-18-1996	
	B6	WO	96/06166	A1	Medical Research Council	02-29-1996	
	B7	WO	96/20951	A1	Massachusetts Institute of Technology	07-11-1996	
	B8	WO	96/40892	A1	BASF AG	12-19-1996	
	B9	WO	96/41865	A1	Ariad Gene Therapeutics, Inc.	12-27-1996	
	B10	WO	97/10337	A1	Baylor College of Medicine	03-20-1997	
	B11	WO	97/31113	A1	Ariad Pharmaceuticals, Inc.	08-28-1997	
	B12	WO	98/25947	A1	Bristol-Myers Squibb Company	06-18-1998	
	B13	WO	98/53057	A1	Medical Research Council	11-26-1998	
	B14	WO	99/01549	A1	BASF Aktiengesellschaft	01-14-1999	
	B15	WO	99/10510	A2	Ariad Gene Therapeutics, Inc.	03-04-1999	
	B16	WO	00/73434	A1	Gendax Limited	12-07-2000	

Examiner Signature	<i>D. Sullivan</i>	Date	5/24/01
--------------------	--------------------	------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.



Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/996,484		
		Filing Date	November 28, 2001		
		First Named Inventor	CHOO		
		Group Art Unit	1643 / 636		
Examiner Name	Unassigned	D Sullivan			
Sheet	2	of	2	Attorney Docket Number	8325-2008 (G8-US1)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Dickinson et al., "Inhibition of RNA Polymerase II Transcription in Human Cells by Synthetic DNA-Binding Ligands," <i>PNAS</i> 95(22):12890-12895 (1998)	
	C2	Dickinson et al., "Inhibition of Ets-1 DNA Binding and Ternary complex Formation Between Ets-1, NF-KappaB, and DNA by a Designed DNA-Binding Ligand," <i>Journal of Biological Chemistry</i> 274(18):12765-12773 (1999)	
	C3	Gatz et al., "Stringent Repression and Homogenous De-Repression by Tetracycline of a Modified CaMV 35S Promoter in Intact Transgenic Tobacco Plants," <i>Plant Journal</i> 2(3):397-404 (1992)	
	C4	Gottesfeld et al., "Regulation of Gene Expression by Small Molecules," <i>Nature</i> 387(6629):202-205 (1997)	
	C5	Weinmann et al., "Chimeric Transactivator Allows Tetracycline-Responsive Gene Expression in Whole Plants," <i>Plant Journal</i> 5(4):559-569 (1994)	

Examiner Signature	<i>D Sullivan</i>	Date	5/21/04
--------------------	-------------------	------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.